OTCMKTS:BCTXF BriaCell Therapeutics (BCTXF) Stock Price, News & Analysis → Better than Bitcoin? The Biotech Stock with 46,751% Potential (From Behind the Markets) (Ad) Free BCTXF Stock Alerts $2.24 +0.05 (+2.28%) (As of 04/25/2024 ET) Add Compare Share Share Today's Range$2.15▼$2.2650-Day Range$2.02▼$3.5752-Week Range$3.25▼$17.50Volume29,085 shsAverage Volume1,859 shsMarket Capitalization$1.73 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisChartHeadlinesStock AnalysisChartHeadlines Get BriaCell Therapeutics alerts: Email Address Ad Weiss RatingsThe Next Step of Their Control Is Here …Earlier this week, Section 702 of the Foreign Intelligence Surveillance Act (FISA) was renewed for an additional two years. What does this mean? It means the government has more time — and more ways — to surveil and control you.4 simple steps to protect your privacy and money before it’s too late. About BriaCell Therapeutics Stock (OTCMKTS:BCTXF)BriaCell Therapeutics Corp. operates as a clinical-stage biotechnology company that specializes in immunotherapy for advanced breast cancer. It is advancing its targeted immunotherapy program by conducting a Phase I/IIA clinical trial with Bria-IMT in combination with an immune checkpoint inhibitor and a companion diagnostic test, BriaDx, to identify patients to benefit from Bria-IMT. The company was founded by Charles L. Wiseman and Isaac B. Maresky on July 26, 2006 and is headquartered in West Vancouver, Canada.Read More BCTXF Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart BCTXF Stock News HeadlinesApril 25, 2024 | americanbankingnews.comBriaCell Therapeutics (OTCMKTS:BCTXF) Stock Price Down 5.6%April 21, 2024 | morningstar.comBriaCell Therapeutics Corp Ordinary Shares - New BCTApril 26, 2024 | Weiss Ratings (Ad)The Next Step of Their Control Is Here …Earlier this week, Section 702 of the Foreign Intelligence Surveillance Act (FISA) was renewed for an additional two years. What does this mean? It means the government has more time — and more ways — to surveil and control you.February 2, 2024 | msn.comBriaCell’s Shareholders Approve Directors and AuditorsJanuary 4, 2024 | finanznachrichten.deBriaCell Therapeutics Corp.: BriaCell Images Confirm Robust Anti-Tumor Activity in Patient with "Eye-Bulging" Metastatic Breast CancerNovember 15, 2023 | businesswire.comMiNA Therapeutics Highlights Preclinical Research on RNA Activation (RNAa) Therapeutics Presented at the Oligonucleotide Therapeutics Society (OTS) Annual MeetingOctober 25, 2023 | finance.yahoo.comBriaCell Forms Medical Advisory Board of Distinguished Breast Cancer Specialists to Advance its Lead Oncology CandidateOctober 20, 2023 | finance.yahoo.comOctober is Breast Cancer Awareness Month – BriaCell is Leading the Fight with its Innovative TechnologyApril 26, 2024 | Weiss Ratings (Ad)The Next Step of Their Control Is Here …Earlier this week, Section 702 of the Foreign Intelligence Surveillance Act (FISA) was renewed for an additional two years. What does this mean? It means the government has more time — and more ways — to surveil and control you.September 26, 2023 | theglobeandmail.comClosing Bell: Briacell Therapeutics Corp flat on Monday (BCT)September 10, 2023 | msn.comBriaCell Therapeutics: Poised To Move To Advanced Trials, But An Unconvincing ThesisSeptember 8, 2023 | finance.yahoo.comBriaCell Reports Benchmark-Beating Patient Survival and Clinical Benefit in Advanced Metastatic Breast CancerAugust 18, 2023 | finance.yahoo.comBriaCell Therapeutics Corp. Announces Voting Results From Special MeetingAugust 17, 2023 | msn.comBriaCell receives NCI grant for cancer platform developmentJuly 22, 2023 | theglobeandmail.comBriaCell Therapeutics: Stocks Undervalued by Analyst Consensus on TSX (BCT)June 28, 2023 | markets.businessinsider.comBriaCell Therapeutics (BCT) Gets a Buy Rating from H.C. WainwrightMay 25, 2023 | marketwatch.comBriaCell Therapeutics in Definitive Agreement to Spin Off Certain AssetsMay 25, 2023 | msn.comBriaCell to spin out BriaPro TherapeuticsApril 27, 2023 | theglobeandmail.comBriaCell Therapeutics: Top 25 Performing Stocks Year-to-Date on Toronto Stock Exchange (BCT)April 7, 2023 | theglobeandmail.comClosing Bell: Briacell Therapeutics Corp down on Thursday (BCT)April 1, 2023 | morningstar.comToronto Stocks Advance as Banking Sector Sentiment Improves; BriaCell Slides on Spinoff PlansMarch 30, 2023 | marketwatch.comBriaCell Therapeutics to Spin Off Certain AssetsFebruary 23, 2023 | marketwatch.comBriaCell Sees Positive Survival Data in Ongoing TrialFebruary 23, 2023 | finance.yahoo.comBriaCell Reports Positive Survival Data in Advanced Metastatic Breast CancerJanuary 23, 2023 | marketwatch.comBriaCell to Investigate Potential Stock ManipulationJanuary 12, 2023 | stockhouse.comBriaCell Announces New Patent Issuance, Bria-OTS(TM) IND Timing Guidance, and Additional Clinical Sites to Boost EnrolmentJanuary 10, 2023 | msn.comBriaCell to get US, Australian patent linked to personalized cancer immunotherapySee More Headlines Receive BCTXF Stock News and Ratings via Email Sign-up to receive the latest news and ratings for BriaCell Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Industry, Sector and Symbol Stock ExchangeOTCMKTS SectorMedical Industry Pharmaceutical Preparations Sub-IndustryN/A Current SymbolOTCMKTS:BCTXF CUSIPN/A CIKN/A Webwww.briacell.com Phone(604) 921-1810FaxN/AEmployees5Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)($3.84) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-3,680,000.00 Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on Assets-786.77% Debt Debt-to-Equity RatioN/A Current Ratio0.07 Quick Ratio0.07 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value($4.55) per share Price / Book-0.49Miscellaneous Outstanding Shares772,000Free FloatN/AMarket Cap$1.73 million OptionableNot Optionable Beta1.09 10 "Recession Proof" Stocks That Will Thrive in Any MarketWhich stocks are likely to thrive in today's challenging market? Click the link below and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.Get This Free Report Key ExecutivesWilliam V. WilliamsPresident, Chief Executive Officer & DirectorGadi LevinChief Financial Officer & SecretaryFarrah DeanManager-Corporate Development & IR ContactKey CompetitorsPainReformNASDAQ:PRFXAoxing PharmaceuticalOTCMKTS:AOXGAcerus PharmaceuticalsOTCMKTS:ASPCFMallinckrodtOTCMKTS:MNKKQBio-PathNASDAQ:BPTHView All Competitors BCTXF Stock Analysis - Frequently Asked Questions How have BCTXF shares performed in 2024? BriaCell Therapeutics' stock was trading at $5.85 at the beginning of 2024. Since then, BCTXF stock has decreased by 61.7% and is now trading at $2.24. View the best growth stocks for 2024 here. How do I buy shares of BriaCell Therapeutics? Shares of BCTXF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (OTCMKTS:BCTXF) was last updated on 4/26/2024 by MarketBeat.com Staff From Our PartnersThese AI trades triggered this morning (545% return)Prosper Trading AcademyThe Best AI Stock to Own in the World Today is Trading for Just $25Banyan Hill PublishingConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial MetalsExposed: 10 CENT Crypto to Explode April 20th?True Market InsidersRed Alert: Your Money's Disappearance Act - Banks' Greed Unleashed!Priority GoldThe A.I. story nobody is telling you (Read ASAP)TradeSmithHe Is Giving Away BitcoinCrypto Swap ProfitsMan Who Predicted 2008: “This Will be Worse.”Altimetry Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding BriaCell Therapeutics Corp. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
